Indoprofen

Indoprofen

SCHEMBL10850545

CC(C(=O)O)c1ccc(N2Cc3ccccc3C2=O)cc1.[NaH]

nearest known ligand 0.97

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PTGS1PTGS2

The experimentally established mechanism targets of Indoprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 known ✓ P35354 1/20 0.45
NPC1 O15118 4/20 0.97
RAB9A P51151 4/20 0.97
SMN1; SMN2 Q16637 3/20 0.97
PKM P14618 3/20 0.97
TP53 P04637 2/20 0.97
LMNA P02545 2/20 0.97
MEN1 O00255 1/20 0.97
CYP2D6 P10635 1/20 0.97
CYP2C19 P33261 1/20 0.97
KMT2A Q03164 1/20 0.97
PGR P06401 1/20 0.97
CYP3A4 P08684 1/20 0.97
GAA P10253 1/20 0.97
NFKB1 P19838 1/20 0.97
DRD1 P21728 1/20 0.97
HTT P42858 1/20 0.97
NFKB2 Q00653 1/20 0.97
RELA Q04206 1/20 0.97
HDAC6 Q9UBN7 1/20 0.97

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Indoprofen SCHEMBL10600175 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
Indoprofen SCHEMBL29361927 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
(R)-Indoprofen SCHEMBL30910963 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
(R)-Indoprofen SCHEMBL5419435 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
(R)-Indoprofen SCHEMBL30910962 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
Dexindoprofen SCHEMBL286896 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
Indoprofen SCHEMBL25137 0.99 NPC1 (1.00) NPC1RAB9ASMN1; SMN2PKMTP53
SCHEMBL10115277 0.91 NPC1 (0.85) NPC1RAB9ASMN1; SMN2PKMTP53
SCHEMBL15695571 0.91 NPC1 (0.85) NPC1RAB9ASMN1; SMN2PKMTP53
SCHEMBL11550044 0.88 NPC1 (0.81) NPC1RAB9ASMN1; SMN2PKMTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260053978-A1 Biodegradable Metallic - Polymeric Composite Prosthesis for Heart Valve Replacement UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2026-02-26 US disclosed
US-20260049177-A1 PREPOLYMERS AND COMBINATIONS THEREWITH FOR WOUND REGENERATION Sunnybrook Research Institute (US) 2026-02-19 US disclosed
US-12544213-B2 Bioerodible wraps and uses therefor University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2026-02-10 US disclosed
EP-3347063-B1 BI-LAYER EXTRA CELLULAR MATRIX SCAFFOLDS AND USES THEREFOR UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) 2025-11-19 EP disclosed
EP-4615512-A1 PREPOLYMERS AND COMBINATIONS THEREWITH FOR WOUND REGENERATION Sunnybrook Research Institute (CA) 2025-09-17 EP disclosed
US-20250242027-A1 Magnetic Delivery System and Hydrogel Fixative for Therapeutic Cells VANDERBILT UNIVERSITY 2025-07-31 US disclosed
US-20250144035-A1 Method of Increasing Epithelial Permeability Using Nanoparticles CARNEGIE MELLON UNIVERSITY 2025-05-08 US disclosed
US-12280112-B2 Magnetic delivery system and hydrogel fixative for therapeutic cells University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-04-22 US disclosed
WO-2025034963-A9 CHOLESTEROL-OLIGONUCLEOTIDE TETHERS WITH APTAMERS FOR LIGAND DISPLAY AND EXTRACELLULAR VESICLE FUNCTIONALIZATION CARNEGIE MELLON UNIVERSITY (US) 2025-04-10 WO disclosed
US-12268773-B2 Shear-thinning therapeutic composition, and related methods University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-04-08 US disclosed
US-20210113519-A1 Compositions and Methods for Modulating Permeability of Biological Barriers CARNEGIE MELLON UNIVERSITY 2021-04-22 US disclosed
EP-3755267-A1 EXTRACTS FOR THE REGENERATION OF LIGAMENTS University of Pittsburgh - of the Commonwealth System of Higher Education (US) 2020-12-30 EP disclosed
EP-3651789-A1 METHOD OF INCREASING EPITHELIAL PERMEABILITY USING NANOPARTICLES Carnegie Mellon University (US) 2020-05-20 EP disclosed
US-20200129444-A1 Method of Increasing Epithelial Permeability Using Nanoparticles CARNEGIE MELLON UNIVERSITY 2020-04-30 US disclosed
WO-2019204434-A1 COMPOSITIONS AND METHODS FOR MODULATING PERMEABILITY OF BIOLOGICAL BARRIERS CARNEGIE MELLON UNIVERSITY (US) 2019-10-24 WO disclosed
WO-2019165185-A1 EXTRACTS FOR THE REGENERATION OF LIGAMENTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2019-08-29 WO disclosed
CN-105142611-B Topical composition and the method for treating topical condition 佩丽泰克医药有限公司 2019-06-04 CN disclosed
WO-2019014559-A1 METHOD OF INCREASING EPITHELIAL PERMEABILITY USING NANOPARTICLES CARNEGIE MELLON UNIVERSITY (US) 2019-01-17 WO disclosed
CN-105142611-A Topical compositions and methods of treatment of topical disorders PERITECH PHARMA LTD 2015-12-09 CN disclosed
EP-0167958-A2 Oral solid pharmaceutical form with sequential action for the administering of drugs with ulcerogenic side effect LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A. (IT) 1986-01-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12544213-B2 Bioerodible wraps and uses therefor MEF2D, TNNT2, VEGFA PTGS2 3087/4885NPC1 4355/4885RAB9A 3866/4885
US-20210113519-A1 Compositions and Methods for Modulating Permeability of Biological Barriers FABP2, SI, VIP PTGS2 643/4885NPC1 805/4885RAB9A 1813/4885
US-20260049177-A1 PREPOLYMERS AND COMBINATIONS THEREWITH FOR WOUND REGENERATION PREP, ANPEP, SPPL2B PTGS2 566/4885NPC1 4550/4885RAB9A 3519/4885
US-20260053978-A1 Biodegradable Metallic - Polymeric Composite Prosthesis for Heart Valve Replacement TNNT2, EED, CAD PTGS2 1848/4885NPC1 4554/4885RAB9A 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.